A leading AI software provider for biopharma research and development, has announced a new agreement with argenx. The two companies have entered a two-year enterprise agreement focused on AI-driven preclinical drug discovery. Under the agreement, argenx will deploy EMET across its organization. EMET is BenchSci’s agentic research environment for preclinical drug discovery. The platform will support scientists across argenx’s global research organization.
EMET will specifically aid teams involved in pre-clinical, computational and drug development workflows. The agreement also constitutes an important step in BenchSci’s European biopharma expansion. BenchSci was selected by argenx following a competitive evaluation process led by scientists at argenx. The pact, therefore, underscores the platform’s increasing importance in scientific research settings.
The selection also demonstrates the increasing interest in AI-driven tools across biopharma research. Furthermore, scientists can use such platforms to support complex research and development activities.
EMET Supports Complex Scientific Workflows
BenchSci designed EMET to provide scientists with an agentic research environment. The platform brings several research resources together within one environment. Just as AI coding gives every developer a team of expert engineers, EMET gives every scientist an agentic team of PhD scientists – unifying data, models, software packages, workflows, and scientific reasoning into a single environment purpose-built for preclinical R&D.
The platform reasons across 38M+ open- and closed-access scientific publications. It also uses a proprietary knowledge graph and clinical data. Additionally, EMET works with pre-print data and more than 100+ curated scientific databases. These resources help the platform handle complex, multi-step scientific workflows.
As a result, EMET aims to deliver traceable and actionable insights throughout the drug discovery journey. The platform combines scientific reasoning with data and computational resources.This approach can support researchers as they move through different stages of preclinical R&D. It can also help teams work with broader scientific evidence during drug development.
The agreement therefore places AI-driven preclinical drug discovery at the center of a broader research strategy. It also reflects the growing role of agentic technology within pharmaceutical research.
“When scientists run a competitive evaluation and choose the platform themselves, it means the platform is earning trust where it matters most — at the bench, not in the boardroom,” said Liran Belenzon, CEO & Co-Founder, BenchSci.
argenx Tests Always-On Scientific Support
For argenx, the agreement will provide scientists with access to EMET across its global research organization. The company will use the platform across several scientific and development workflows. The deployment will cover preclinical research and computational activities. It will also support broader drug development workflows across the organization.
Consequently, the partnership will give argenx scientists access to AI-supported research capabilities. The platform can help researchers navigate scientific evidence and complex workflows. Tim Van Acker, Director of Business Development, argenx, also highlighted the company’s approach to the technology.
“We think of BenchSci’s EMET as a scientist in your pocket – always available, always reasoning across the evidence. For argenx, this is about testing whether this kind of always-on scientific support can meaningfully accelerate preclinical development and our broader computational and drug development workflows,” said Tim Van Acker, Director of Business Development, argenx.
The deal gives argenx the opportunity to evaluate always-on scientific support in its research operations. At the same time, BenchSci has another chance to grow its footprint in global biopharma. Overall, the partnership strengthens the focus on AI-driven pre-clinical drug discovery.” It also underscores the increasing use of AI in scientific research and drug development.
Biopharma companies are taking a closer look at agentic platforms for more efficient research. Technologies that combine scientific data, models, workflows and reasoning can therefore increase in importance. BenchSci’s deal with argenx is only one of the developments in this evolving area. The alliance joins artificial intelligence (AI) technology with proven scientific research techniques.
EMET will now become part of argenx’s global research organization through a two-year agreement. This will give scientists one more technology platform for preclinical and computational research.
Explore Health Tech Insiders for the latest medical innovations and reliable strategic insights driving the future of technology-driven healthcare transformation.
News Source: Businesswire.com
